A recent study suggests that Paxlovid is ineffective at treating symptoms in people with mild illness or those who have been ...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, announced on April 15 that it would carry out global ...
The Wisconsin Department of Health Services (DHS) reminded residents that its COVID-19 treatment program will end on ...
A collaboration between the University of Tasmania and Royal Hobart Hospital Pathology has revealed the consequences of using ...
According to scientists, the man, who had a weakened immune system, was a perfect breeding ground for deadly new strains of ...
It was one of the first available antiviral medications and has been used in the treatment of COVID-19 in Australia for those at risk of severe disease. Today, molnupiravir remains available for ...
Researchers reported on the prevalence, features, and risk factors associated with COVID-19 breakthrough infections among individuals with idiopathic inflammatory myopathies.
The program, initially planned to end in 2023, was extended to April 2024 due to the success of the program and high cases of ...
After previously expected to conclude at the end of 2023, the Wisconsin Department of Health Services said Monday that its ...
TaiGen’s business partner, Joincare Pharma completes influenza antiviral TG-1000 phase III study: Taipei, Taiwan Friday, April 19, 2024, 10:00 Hrs [IST] TaiGen Biotechnology Com ...
The majority of Aussies who are at a higher risk of becoming seriously ill from Covid-19 don’t have a plan in place with ...